Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Privacy Policy
  • Contact US

Insight, China's Pharmaceutical Industry Fineline Info & Tech is a comprehensive global pharmaceutical database that spans the entire product lifecycle. Its mission is to equip professionals and executives across all sectors of the life sciences industry with a standardized data language, offering a holistic view of the Chinese pharmaceutical competitive landscape. Flcube.com furnishes critical data essential for informed decision-making, drawing on global industry news, policy insights, competitive intelligence, and advanced analytical tools.

Company Deals PIC

Suzhou AsiFlyer Biotechnology Secures Exclusive Worldwide License from ShanghaiTech University for AI‑Designed Recombinant Botulinum Toxin Patent

Fineline Cube Sep 8, 2026
Company Deals PIC

Liaocheng University and Shanghai Maiboxing Biotechnology Sign RMB 19 Million Pact to Co‑Develop LCUGZ1007 – Next‑Generation E‑PDC Probody Drug Conjugate

Fineline Cube Sep 8, 2026
Company Deals PIC

China Biotech’s Panboron BNCT Hospital Signs Strategic Pact with OncoCare Cancer Centre HK – Launching Cross‑Border BNCT Oncology Cooperation

Fineline Cube Sep 8, 2026
Company Deals PIC

Guangdong Taienkang Completes Capital Increase in Procapzoom – Secures Exclusive China Rights to World‑First Ocular Surface Cell Therapy SZ018

Fineline Cube Sep 8, 2026
Company Deals PIC

HepaBio Therapeutics Raises Series A Strategic Funding From TriApex to Advance Organoid Technology and Next‑Generation Drug R&D Systems

Fineline Cube Sep 7, 2026
Company Deals PIC

Suzhou AsiFlyer Biotechnology Secures Exclusive Worldwide License from ShanghaiTech University for AI‑Designed Recombinant Botulinum Toxin Patent

Fineline Cube Sep 8, 2026
Company Drug

Hengrui Pharmaceuticals Wins NMPA Clinical Trial Approval for SHR‑1179 – First‑in‑Class Biological Candidate for Weight Management

Fineline Cube Sep 8, 2026
Company Drug

Hualan Bio Wins NMPA Clinical Trial Approval for Novel Influenza mRNA Vaccine – China’s Vaccine Major Pushes into mRNA Platform

Fineline Cube Sep 8, 2026
Company Drug Medical Device

China’s Q1 2025 Pharmaceutical Exports Rise 4.39% Despite Import Decline

Fineline Cube May 14, 2025

The China Chamber of Commerce for Import and Export of Medicines and Health Products (CCCMHPIE)...

Company Deals

Porton Pharma Collaborates with Henan Hualong for MATC Therapy Development

Fineline Cube May 14, 2025

China-based Contract Development and Manufacturing Organization (CDMO) Porton Pharma Solutions Ltd has entered into a...

Company

Bayer Reports Flat Q1 Revenue amid Crop Science Decline

Fineline Cube May 14, 2025

German pharmaceutical and chemical giant Bayer (ETR: BAYN) released its Q1 2025 financial report, recording...

Company Drug

Medilink Therapeutics Gains FDA IND Approval for VEGF-Targeted ADC YL242

Fineline Cube May 14, 2025

Suzhou-based Medilink Therapeutics announced that it has received Investigational New Drug (IND) approval from the...

Company Drug

Zhongsheng Pharma’s Anruiwei Shows Promising Results in Pediatric Influenza A Study

Fineline Cube May 14, 2025

China-based Guangdong Zhongsheng Pharmaceutical Co., Ltd (SHE: 002317) announced the topline analysis data from the...

Company Drug

Sinovac Biotech Gains Hong Kong Approval for Influenza Vaccines

Fineline Cube May 14, 2025

China-based Sinovac Biotech Ltd (NASDAQ: SVA) announced that it has received marketing approvals from the...

Company

InnoCare Pharma Reports 129.92% Revenue Surge in Q1 2025, Turns Profitable

Fineline Cube May 14, 2025

Beijing-based biotech InnoCare Pharma (HKG: 9969, SHA: 688428) released its Q1 2025 financial report, recording...

Drug Policy / Regulatory

NMPA Releases 92nd Batch of Reference Drugs for Generic Quality Evaluation

Fineline Cube May 14, 2025

The National Medical Products Administration (NMPA) has released the 92nd batch of reference drugs for...

Company Deals

Gan & Lee Pharmaceuticals Signs PDP Agreement with Brazilian Health Ministry

Fineline Cube May 14, 2025

Gan & Lee Pharmaceuticals (SHA: 603087) announced the signing of Parcerias para o Desenvolvimento Produtivo...

Company Drug

Zelgen Biopharmaceuticals Submits New Indication Application for Jacktinib in Severe Alopecia Areata

Fineline Cube May 14, 2025

China-based Suzhou Zelgen Biopharmaceuticals Co., Ltd (SHA: 688266) announced that it has submitted a new...

Company Deals

Meheco Acquires Golden Harvest for E-commerce Expansion

Fineline Cube May 14, 2025

China Meheco Group Co., Ltd (SHA: 600056) announced the acquisition of 100% stake in Beijing...

Company

JD Healthcare Reports 25.5% Revenue Growth in Q1 2025

Fineline Cube May 14, 2025

JD Healthcare (HKG: 6618), a subsidiary of China’s e-commerce giant JD.com (NASDAQ: JD), released its...

Company Drug

Ocumension Therapeutics Receives Approval for OT-703 Real-World Study in China

Fineline Cube May 14, 2025

Chinese ophthalmology specialist Ocumension Therapeutics (HKG: 1477) announced that it has received approval in China...

Company

Legend Biotech’s Q1 2025 Results Highlight Carvykti Sales Growth

Fineline Cube May 14, 2025

China-based Legend Biotech Corporation (NASDAQ: LEGN) released its Q1 2025 financial report, highlighting significant revenue...

Company Deals

Sanyou Biopharmaceuticals and TransReco Biotechnology Partner to Advance Novel Drug Formulations

Fineline Cube May 14, 2025

China-based Sanyou Biopharmaceuticals (Shanghai) Co., Ltd. and TransReco (Wenzhou) Biotechnology Co., Ltd. announced a strategic...

Company Deals

Novo Nordisk Partners with PingAn Good Doctor to Promote Scientific Weight Loss in China

Fineline Cube May 14, 2025

Denmark-based Novo Nordisk (NYSE: NVO, CPH: NOVO-B) has formed a strategic partnership with China’s Ping...

Company Drug

BRL Medicine Reports Positive Results for TyU19 in Refractory SLE Trial

Fineline Cube May 14, 2025

Shanghai-based BRL Medicine Inc. announced positive results from an investigator-initiated trial (ITT) evaluating its allogeneic...

Company Deals

InnoCare Pharma Partners with Westlake University for Innovative Drug Research

Fineline Cube May 14, 2025

Beijing-based biotech InnoCare Pharma (HKG: 9969, SHA: 688428) announced a strategic partnership agreement with Westlake...

Company Drug

Betta Pharmaceuticals Secures Macau Approval for Ensartinib

Fineline Cube May 13, 2025

China-based Betta Pharmaceuticals (SHE: 300558) announced a market approval filing in Macau for its ensartinib,...

Company Deals

OYMotion Technologies Secures RMB 100 Million in Series B++ Funding for Exoskeleton Robots

Fineline Cube May 13, 2025

Shanghai-based OYMotion Technologies Co., Ltd, a high-tech company specializing in brain-computer interface and robotics technology,...

Posts pagination

1 … 214 215 216 … 717

Recent updates

  • Hengrui Pharmaceuticals Wins NMPA Clinical Trial Approval for SHR‑1179 – First‑in‑Class Biological Candidate for Weight Management
  • Hualan Bio Wins NMPA Clinical Trial Approval for Novel Influenza mRNA Vaccine – China’s Vaccine Major Pushes into mRNA Platform
  • METiS Therapeutics Partners with Hengrui Pharma – Deploying AiTEM AI Formulation Platform at China’s Leading Drugmaker
  • Suzhou AsiFlyer Biotechnology Secures Exclusive Worldwide License from ShanghaiTech University for AI‑Designed Recombinant Botulinum Toxin Patent
  • Sun-Novo Pharmaceutical and DeepMed Technology Sign Strategic Pact on AI‑Driven Drug R&D – Building Closed‑Loop “AI Design + Wet‑Lab Validation” Discovery System
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • PIC
  • Policy / Regulatory
  • R&D

You Missed

Company Drug

Hengrui Pharmaceuticals Wins NMPA Clinical Trial Approval for SHR‑1179 – First‑in‑Class Biological Candidate for Weight Management

Company Drug

Hualan Bio Wins NMPA Clinical Trial Approval for Novel Influenza mRNA Vaccine – China’s Vaccine Major Pushes into mRNA Platform

Others

METiS Therapeutics Partners with Hengrui Pharma – Deploying AiTEM AI Formulation Platform at China’s Leading Drugmaker

Company Deals PIC

Suzhou AsiFlyer Biotechnology Secures Exclusive Worldwide License from ShanghaiTech University for AI‑Designed Recombinant Botulinum Toxin Patent

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

© 2026 Fineline Information & Technology. Independent intelligence on China's pharmaceutical industry. Not investment advice. | BlogData by Themeansar.